Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Mol Graph Model. 2010 Nov;29(3):436-42. doi: 10.1016/j.jmgm.2010.08.006. Epub 2010 Sep 21.

Acetylenic inhibitors of ADAM10 and ADAM17: in silico analysis of potency and selectivity.

Author information

  • 1Department of Chemistry, St. Edward's University, 3001 South Congress Ave., Austin, TX 78704, USA. healy@stedwards.edu

Abstract

The matrix metalloproteinase family has been a pharmaceutical target for most of the last three decades, but success has been hampered by unwanted side effects caused by lack of selectivity, poor oral bioavailability and decreased potency in vivo. The surface-expressed metalloproteinases ADAM10 and ADAM17, the latter also referred to as TACE, play important roles in various physiological processes, especially involving tissue repair and development. Because of its role in the release of the cytokine TNF-α TACE has been a key target for pharmaceutical intervention in the treatment of rheumatoid arthritis. An extensive body of structural activity data has been developed for a series of small molecule inhibitors of TACE based on a sulfonamide scaffold containing key acetylenic substituents. We have undertaken an extensive molecular modeling study of select members of this ligand group to better understand the structural nuances involved in the development of ever more potent TACE inhibitors, and identify those elements of structure-based design that would enhance the selectivity of such inhibitors for TACE over ADAM10. Results include the identification of a flexible loop, comparable to that found in other MMPs that plays a subtle, yet significant, role in determining inhibitor potency.

Copyright © 2010 Elsevier Inc. All rights reserved.

PMID:
20863729
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk